Terray Therapeutics

Unlocking the potential of AI-driven drug discovery with premium chemical data at unrivaled scale

[Terray Therapeutics @Terray_Tx]

https://t.co/NAP5r2GPqf

[Terray Therapeutics @Terray_Tx]

Terray has been built at the intersection from the moment it was founded, and we recently expanded our digital and visual footprint to reflect this.

Our CEO, Jacob Berlin, PhD and CFO, Eli Berlin went into the philosophy at Terray, what makes us stand apart, and how we are bringing together experimentation and AI to transform the speed, cost, and, most importantly, success rate of small molecule drug discovery.

Check out our new video about our approach and how EMMI, our platform for drug discovery and development, enables our teams to innovate.

For the full blog check out the link in comments!

[Terray Therapeutics @Terray_Tx]

Partnerships are core to Terray - from our collaborations with Bristol Myers Squibb, Gilead Sciences, and Calico Life Sciences to our co-development work with Odyssey Therapeutics.

On Wednesday, April 22 at UNLOCK AI Science in San Francisco, our Co-Founder Eli Berlin will join the panel - "Dealmaking and Partnerships: Who's Actually Writing the Checks" - to explore what it really takes to build partnerships around AI-native drug discovery platforms.
He'll be joined by Jonah Cool (Anthropic), Sarah H. Nam (AbbVie), Stacy Feld (Johnson & Johnson), and Chris Leiter (Atria Ventures) for what will be a candid conversation about how the partnership landscape for AI-native platforms is evolving. 

If you're interested in dealmaking at the intersection of AI and life sciences, we hope to see you on the 22nd!

@EliBerlin3 @JCoolScience @chrisleiter_

[Terray Therapeutics @Terray_Tx]

Benchling's latest Transcribed episode dives deep into how Terray is wiring hardware, data, and AI into a single engine for small-molecule drug discovery. Our CEO and founder, Jacob Berlin, sat down with Benchling’s founder, @sajithw, to discuss the importance of pairing precise, proprietary data at scale with industry-leading AI models – and most importantly, having it all deeply integrated with workflows in the lab. EMMI takes these elements and turns them into agentic, end to end workflows.

They cover why models alone aren’t a moat, how EMMI Select tackles “AI abundance”, and why synthetically constrained generative models are the only practical future. If you care about building real medicines at the intersection of experimentation and machine intelligence, please listen and subscribe!

Thanks to the @benchling team!

Available on all podcast platforms and YouTube!
https://t.co/g9hX0pbUCJ

[Terray Therapeutics @Terray_Tx]

Join our incredible team!

[johnparkhill @j0hnparkhill]

-- Hiring ML Engineers time! --
Are you a smart person who wants to make therapeutics to help people using your ML chops? We will hire two engineers. We don't care about your pedigree, just your skills. Prove them by attempting the exercise linked below (<6 hours) 🧵

[Terray Therapeutics @Terray_Tx]

Terray Therapeutics is heading to ACS Spring 2026.

Our co-founder and CEO, Jacob Berlin, Ph.D., will speak at the Presidential Event on “Human, Computer and Artificial Intelligence,” where he’ll share how a chemistry-first, AI-native approach can reshape small molecule discovery.

If you’ll be at ACS Spring 2026, join the session to hear what we’ve learned so far—and what’s next—for AI in drug discovery.

#ACS150 #DrugDiscovery

[Terray Therapeutics @Terray_Tx]

Last week we announced a big leap forward for universal potency models with EMMI Predict: TerraBind. TerraBind delivers best-in-class potency prediction while running 26x faster and reducing inference cost by 96% relative to standard industry potency models.

A key driver of this performance is our collaboration with @nvidia and the integration of the NVIDIA cuEquivariance library. By centering its computational core on triangle attention and multiplication, TerraBind's architecture is uniquely positioned to fully leverage cuEquivariance's GPU-optimized kernels, providing a 3-4x speedup compared to standard implementations.

With EMMI Predict: TerraBind at the center of our Generate-Predict-Select workflow, this combination of proprietary data, purpose-built models, and NVIDIA-accelerated hardware is transforming how we discover and optimize small-molecule therapeutics. We're excited to keep pushing the boundaries of predictive chemistry with partners like NVIDIA as we work to bring better medicines to patients faster.

Read our blog https://t.co/ShSfob1PX4
Read our arxiv paper https://t.co/VrQurS3gPV

[Terray Therapeutics @Terray_Tx]

Today we announced EMMI Predict: TerraBind, our universal potency model that dramatically expands Terray’s ability to move molecules to the clinic faster. Far outpacing publicly available models, TerraBind is a cornerstone of Terray’s end-to-end workflow for small molecule discovery and development.

Read our blog: https://t.co/ShSfob1PX4

[AWS Startups @AWSstartups]

Thanks to all the attendees and partners who came out for @TechCrunch Disrupt to check out AWS’ breakout session with founders from @BigHatBio & @Terray_Tx, and the AWS San Francisco Startup Loft afterparty. 🎉

For more on AWS Startup Loft events, visit: https://t.co/IHxzqg6gKM

[Terray Therapeutics @Terray_Tx]

Today’s the day! We hope to see you at 10 am PDT for “Tech-Driven Biology and Chemistry: Solving Science’s Hardest Problems at Scale” at #Disrupt2022. We'll be talking with @BigHatBio and @awscloud about:
🟢 Company Building
🟢 Science Fact vs Fiction
🟢 The Future of Medicine

[Calico @calico]

We are pleased to announce a new collaboration with @Terray_Tx focused on the discovery and development of novel small molecule therapeutics for diseases of #aging, including #cancer. To learn more: https://t.co/37ErlvbgGy

[Terray Therapeutics @Terray_Tx]

Terray is proud to announce a multi-target collaboration with @calico. The Terray and Calico teams will work together to discover and develop small molecule therapeutics for diseases of aging, including cancer. Read more here: https://t.co/XsoaVTn2dT

[Terray Therapeutics @Terray_Tx]

You won’t want to miss this – mark your calendars for Terray’s panel at @TechCrunch’s #Disrupt2022! We’re beyond excited to talk about solving science's hardest problems at scale with our friends at BigHat Biosciences!

[AWS Startups @AWSstartups]

Attending @TechCrunch Disrupt?
Don’t miss the AWS’ breakout session w/leaders in the AI-driven drug discovery market, @BigHatBio & @Terray_Tx on October 19.

Also, join us at the AWS #StartupLoft SF after party for food & drinks October 20.

Register: https://t.co/eFAIdNpZVM

[Terray Therapeutics @Terray_Tx]

We are thrilled to announce the appointment of
Fiona Black, PhD, to our Scientific Advisory Board. Read more about Fiona and how she will support Terray’s mission to advance drug discovery: https://t.co/Oq9fdBYrXb

[Terray Therapeutics @Terray_Tx]

Our CEO @JacobBerlinPhD will be presenting at @MorganStanley's Putting the Tech in Biotech conference tomorrow to discuss how Terray is meeting the challenge of #DrugDevelopment with the chemistry engine and #AI to propel drug discovery into the information age.
#biotech

[Terray Therapeutics @Terray_Tx]

Tonight’s the night! We hope to see you on Clubhouse at 6 PM EDT for “Using chemistry data & AI to speed drug discovery”, the last of @Amazon Web Service’s Startup Innovation series! https://t.co/rHrEbr8nSO
#biotech #startup #chemistry #AI #DrugDiscovery

[Terray Therapeutics @Terray_Tx]

Have you marked your calendar for June 2nd? We’ll be chatting with @marksbirch and Chris Cheng for the AWS Startup Innovation Series, and you won’t want to miss it. Save the date: https://t.co/rHrEbr8nSO
#biotech #startup #AI #DrugDiscovery

[Terray Therapeutics @Terray_Tx]

We're beyond excited to be a part of the @AWSstartups Startup Innovation Series - come join @JacobBerlinPhD, @EliBerlin3, and @nm_dft as they talk about building a #biotech company and how we're using #AI in #DrugDiscovery. https://t.co/rHrEbqQMue

[Terray Therapeutics @Terray_Tx]

Our executive team of pioneers and long-time leaders in #AI, medicinal #chemistry, #biology, #automation, and #nanotechnology have a vision to create a world where transformative therapeutics are at our fingertips. Ready to join #TeamTerray? We are #nowhiring! #biotechjobs

[Terray Therapeutics @Terray_Tx]

Did you miss @JacobBerlinPhD and @EliBerlin3 on @MadronaVentures’s podcast Founded and Funded? Don’t miss their conversation about lessons learned and the future of #AI in biotechnology: https://t.co/JvNtODltVH